Celltrion’s biosimilar 'Remsima' was selected as a treatment ahead of the original drug in Norway Dr
(Yakup Shinmoon)
On Jan 24, Celltrion announced that the world's first antibody biosimilar 'Remsima' was selected as a treatment for rheumatoid arthritis, ankylosing spondylit...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
